Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Pemigatinib in Advanced Malignancies
2021-002207-36Phase 2Active
- Sponsor
- Incyte
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in Non-hematologic malignancy and cancer, sponsored by Incyte. Primary endpoint: Long-term safety and tolerability of pemigatinib. Started Sep 2021; status: active.
02
Drugs
pemigatinib
03
Conditions
Non-hematologic malignancycancer
Beyond the preview
Go deeper on 2021-002207-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002207-36.